Literature DB >> 557770

Improvement in multiple sclerosis during prolonged induced hypothermia.

G R Symington, I R Mackay, T T Currie.   

Abstract

Moderate hypothermia (33 degrees C) was induced for 7 and 3 days, respectively, in two patients with multiple sclerosis. In both patients, striking improvement of clinical signs persisted throughout the period of cooling, indicating the potential for sustained reversal of the neurologic deficit. Hypothermia may aid management of severe acute exacerbations of multiple sclerosis.

Entities:  

Mesh：

Year:  1977        PMID： 557770     DOI： 10.1212/wnl.27.3.302

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  6 in total

1.  Therapeutic hypothermia for neuroprotection: history, mechanisms, risks, and clinical applications.

Authors:  Lioudmila V Karnatovskaia; Katja E Wartenberg; William D Freeman
Journal:  Neurohospitalist       Date:  2014-07

2.  Lowering body temperature with a cooling suit as symptomatic treatment for thermosensitive multiple sclerosis patients.

Authors:  E Capello; M Gardella; M Leandri; G Abbruzzese; C Minatel; A Tartaglione; M Battaglia; G L Mancardi
Journal:  Ital J Neurol Sci       Date:  1995-11

3.  Effects of induced hyperthermia on visual evoked potentials and saccade parameters in normal subjects and multiple sclerosis patients.

Authors:  S Bajada; F L Mastaglia; J L Black; D W Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-09       Impact factor: 10.154

4.  Chronic hypothermia in multiple sclerosis.

Authors:  F Sullivan; M Hutchinson; S Bahandeka; R E Moore
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

5.  Effect of body temperature on visual evoked potential delay and visual perception in multiple sclerosis.

Authors:  D Regan; T J Murray; R Silver
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-11       Impact factor: 10.154

6.  The cooling effect on proinflammatory cytokines interferon-gamma, tumor necrosis factor-alpha, and nitric oxide in patients with multiple sclerosis.

Authors:  Turan Poyraz; Egemen Idiman; Sezer Uysal; Leyla Iyilikci; Serkan Ozakbaş; Esra Coskuner Poyraz; Fethi Idiman
Journal:  ISRN Neurol       Date:  2013-05-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.